E van Werkhoven Selected Research

N,N- dimethyl- N- hexadecyl- 1- octadecylammonium (DDAC)

10/2018	Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
12/2013	Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

E van Werkhoven Research Topics

Disease

11	Breast Neoplasms (Breast Cancer) 02/2021 - 12/2012
8	Neoplasms (Cancer) 01/2021 - 09/2013
3	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 06/2017
3	Urinary Bladder Neoplasms (Bladder Cancer) 02/2018 - 04/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 09/2019
2	Neoplasm Metastasis (Metastasis) 01/2020 - 12/2012
1	Cardiotoxicity 01/2022
1	Clinical Deterioration 01/2021
1	Triple Negative Breast Neoplasms 01/2021
1	Choriocarcinoma 01/2020
1	Squamous Cell Carcinoma of Head and Neck 09/2019
1	Vulvar Neoplasms (Vulvar Cancer) 10/2018
1	Melanoma (Melanoma, Malignant) 10/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 10/2018
1	Prostatic Neoplasms (Prostate Cancer) 10/2018
1	Pathologic Complete Response 08/2018
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 06/2017
1	Hand-Foot Syndrome 06/2017
1	Pruritus (Itching) 01/2017
1	Pain (Aches) 01/2017
1	Noninfiltrating Intraductal Carcinoma (DCIS) 04/2015
1	Thrombocytopenia (Thrombopenia) 09/2013
1	Neutropenia 09/2013
1	Ovarian Neoplasms (Ovarian Cancer) 09/2013
1	Lobular Carcinoma 12/2012

Drug/Important Bio-Agent (IBA)

3	Hormones (Hormone)IBA 01/2021 - 12/2012
2	Capecitabine (Xeloda)FDA Link 01/2022 - 06/2017
2	Pharmaceutical PreparationsIBA 01/2021 - 10/2019
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 10/2018
2	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2018 - 12/2013
2	N,N- dimethyl- N- hexadecyl- 1- octadecylammonium (DDAC)IBA 10/2018 - 12/2013
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2018 - 12/2013
1	Epidermal Growth Factor (EGF)IBA 01/2022
1	Fluorouracil (Carac)FDA LinkGeneric 01/2022
1	Trastuzumab (Herceptin)FDA Link 01/2022
1	pertuzumabIBA 01/2022
1	human ERBB2 proteinIBA 01/2021
1	Methotrexate (Mexate)FDA LinkGeneric 01/2020
1	NivolumabIBA 10/2019
1	olaparibIBA 09/2019
1	Docetaxel (Taxotere)FDA Link 10/2018
1	Coloring Agents (Dyes)IBA 10/2018
1	AnthracyclinesIBA 10/2018
1	Taxoids (Taxanes)IBA 10/2018
1	4-hydroxy-N-desmethyltamoxifenIBA 01/2017
1	Tamoxifen FDA LinkGeneric 01/2017
1	Estrogen Receptor alphaIBA 01/2017
1	Everolimus FDA Link 01/2016
1	Colloids (Colloid)IBA 04/2015
1	Technetium (Technetium 99m)IBA 04/2015
1	Iodine-125IBA 04/2015
1	Phenobarbital (Luminal)FDA Link 12/2013
1	ErbB Receptors (EGF Receptor)IBA 12/2013
1	Gemcitabine FDA Link 09/2013
1	Carboplatin (JM8)FDA LinkGeneric 09/2013

Therapy/Procedure

7	Therapeutics 01/2022 - 09/2013
5	Neoadjuvant Therapy 01/2021 - 12/2012
4	Drug Therapy (Chemotherapy) 01/2022 - 01/2018
4	Radiotherapy 01/2022 - 01/2017
1	Immunotherapy 10/2019
1	Operative Surgical Procedures 10/2018
1	Adjuvant Chemotherapy 10/2018
1	Cystectomy 02/2018
1	Segmental Mastectomy (Lumpectomy) 04/2015
1	Lymph Node Excision (Lymph Node Dissection) 10/2013
1	Induction Chemotherapy 04/2013